Berkley and Jensen Acid Reducer Maximum Strength Disease Interactions
There are 6 disease interactions with Berkley and Jensen Acid Reducer Maximum Strength (ranitidine).
H2 antagonists (applies to Berkley and Jensen Acid Reducer Maximum Strength) GI bleeding
Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Hemorrhage
Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools. These might be serious conditions and the diagnosis needs to be ruled out.
Ranitidine (applies to Berkley and Jensen Acid Reducer Maximum Strength) porphyria
Major Potential Hazard, Moderate plausibility.
Ranitidine may rarely precipitate acute porphyria attacks and should be avoided in patients with a history of acute porphyria.
Ranitidine (applies to Berkley and Jensen Acid Reducer Maximum Strength) hemodialysis
Moderate Potential Hazard, High plausibility.
Ranitidine is partially removed by hemodialysis and should be administered after dialysis.
Ranitidine (applies to Berkley and Jensen Acid Reducer Maximum Strength) liver disease
Moderate Potential Hazard, Low plausibility.
Ranitidine is partially metabolized by the liver. Although dosage reductions are generally not necessary, therapy with ranitidine should be administered cautiously in patients with liver disease. Elevated ALT (SGPT) has been observed in patients receiving ranitidine intravenously at dosages greater than those normally recommended for 5 days or more.
Ranitidine (applies to Berkley and Jensen Acid Reducer Maximum Strength) PKU
Moderate Potential Hazard, High plausibility. Applicable conditions: Phenylketonuria
Zantac (brand of ranitidine) 150 EFFERdose tablets and granules both contain 16.84 mg of phenylalanine per each 150 mg of ranitidine. The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).
Ranitidine (applies to Berkley and Jensen Acid Reducer Maximum Strength) renal dysfunction
Moderate Potential Hazard, High plausibility.
Ranitidine is primarily eliminated by the kidney. Although the drug is generally well-tolerated, the daily dosage should initially be reduced in patients with moderate to severe renal impairment (CrCl < 50 mL/min). If necessary, the daily dosage may be increased with caution.
Switch to professional interaction data
Berkley and Jensen Acid Reducer Maximum Strength drug interactions
There are 149 drug interactions with Berkley and Jensen Acid Reducer Maximum Strength (ranitidine).
Berkley and Jensen Acid Reducer Maximum Strength alcohol/food interactions
There is 1 alcohol/food interaction with Berkley and Jensen Acid Reducer Maximum Strength (ranitidine).
More about Berkley and Jensen Acid Reducer Maximum Strength (ranitidine)
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: H2 antagonists
- Breastfeeding
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.